The Latest Breakthroughs in Immunotherapy for GU Cancers Podcast (2023)

Based on the documented need for additional education in prostate cancer, bladder cancer, and kidney cancer, the AUA has developed AUA Expert Exchange Podcast: Discussions in GU Cancer. The 2023 AUA Expert Exchange Podcast: Discussions in GU Cancer is designed to address very specific learning opportunities and reach the urologic practitioners in an easy, flexible way with smaller, targeted updates. To address the educational needs of the urologic care team, this episode will focus on:

The Latest Breakthroughs in Immunotherapy for GU Cancers (2023)

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 
Lantheus Medical Imaging
Merck & Co., Inc.

Target Audience

  • Urologists

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies.
  2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes.
  3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Course opens: 
12/27/2023
Course expires: 
12/27/2024
Rating: 
0

FACULTY DISCLOSURES

NameCompany NameRelationship TypeEnd Date
Joshi, MonikaAstraZenecaOther-Research funds to Institution via Big Ten Cancer Research ConsortiumCurrent
Joshi, MonikaSeagenConsultant or Advisor10/01/2022
Raman, Jay D.Steba BiotechScientific Study or TrialCurrent

EDUCATION COUNCIL DISCLOSURES

PDF iconEducation Council Disclosures

COI REVIEW WORK GROUP DISCLOSURES

PDF iconCOI Review Work Group Disclosures


AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

AUA ACCREDITATION INFORMATION

Method of Participation: Learners will participate in this online educational activity by listening to the podcast, answering multiple choice questions, examining patient tools and resources and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 0.50 hours

Release Date: December, 2023
Expiration Date: December, 2024

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Please login or register to take this course.